{"organizations": [], "uuid": "d73f4895b73fb02c8a61bbdd6478652073f3003a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-arrowhead-receives-regulatory-clea/brief-arrowhead-receives-regulatory-clearance-to-begin-phase-1-study-of-aro-aat-for-treatment-of-alpha-1-liver-disease-idUSFWN1QC0UY", "country": "US", "domain_rank": 408, "title": "BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.561, "site_type": "news", "published": "2018-02-22T20:38:00.000+02:00", "replies_count": 0, "uuid": "d73f4895b73fb02c8a61bbdd6478652073f3003a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-arrowhead-receives-regulatory-clea/brief-arrowhead-receives-regulatory-clearance-to-begin-phase-1-study-of-aro-aat-for-treatment-of-alpha-1-liver-disease-idUSFWN1QC0UY", "ord_in_thread": 0, "title": "BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "arrowhead pharmaceuticals inc", "sentiment": "negative"}, {"name": "arrowhead pharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Arrowhead Pharmaceuticals Inc:\n* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE\n* ARROWHEAD PHARMACEUTICALS - ANTICIPATES DOSING IN PHASE 1 STUDY WILL BEGIN AROUND END OF MARCH Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T20:38:00.000+02:00", "crawled": "2018-02-23T15:42:10.011+02:00", "highlightTitle": ""}